Novo Nordisk AS (NYSE:NVO)
$ 106.8 0.67 (0.63%) Market Cap: 474.49 Bil Enterprise Value: 471.95 Bil PE Ratio: 35.72 PB Ratio: 27.97 GF Score: 95/100

Novo Nordisk A/S at JPMorgan CEO Call Series Transcript

Sep 14, 2022 / 02:00PM GMT
Release Date Price: $52.52 (-0.94%)
Richard Vosser
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, good afternoon to everyone. A warm welcome from my side, and thanks very much for joining us in the 11th installment of our CEO call series, and today, that's with Novo Nordisk. It's our great pleasure to welcome the CEO of Novo Nordisk, Lars Fruergaard Jorgensen, who is going to speak with us today.

So before I hand over to Lars for a few introductory remarks, I'd just remind everyone that this is primarily a call for your questions. So I'll ask a few questions upfront, but please feel free at any time to ask a question. (Operator Instructions)

With that, I'd like to say thanks very much to Lars for joining us today and hand over to him for a few introductory remarks. Lars, welcome.

Lars Fruergaard Jorgensen;S;President
Novo Nordisk A;CEO & Member of Management Board

/- -

Thank you very much, Richard, and thanks for hosting us today. It's exciting times in Novo Nordisk. We are making good progress on all of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot